Cravath’s London Office Moves to 100 Cheapside
Virginia M. Anderson represents clients in connection with public and private securities offerings and other financing transactions, general corporate matters and mergers and acquisitions. She is a member of the Venture Capital & Growth Equity Practice, where she frequently represents venture capital‑backed companies and investors, as well as other growth‑stage companies and investors, in financing transactions and other matters throughout their lifecycles.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
- IPOs for companies such as Amplify Snack Brands, Jose Cuervo and Vaxxinity, and other public and private equity offerings for companies such as AXIS, Orbotech, Orcosa, People’s United and Replimune
- Debt financings for companies such as AmerisourceBergen, AXIS, Hess Infrastructure Partners, INEOS, Marathon Oil, TransDigm, Valvoline and Xerox
- Investor representations such as a large investor in connection with the $5.1 billion IPO of Lineage; Shaolin Capital Management in its $50 million PIPE investment in connection with the business combination of Bitcoin Depot and GSR II Meteora Acquisition Corp.; Brevan Howard Digital in connection with a variety of investments in digital asset and blockchain companies; and DRI Capital in its equity investment in KalVista Pharmaceuticals
- Representing Route Mobile and its founding shareholders in the sale of a majority stake in Route Mobile to Proximus Group, WiseTech Global in its acquisition of Envase Technologies, Synthomer in its acquisition of OMNOVA, Deutsche Börse in its acquisition of Axioma and Orbotech in its sale to KLA‑Tencor
- Representing various private technology and life sciences companies in general corporate and financing matters, including those involving traditional and synthetic royalty interests
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
- IPOs for companies such as Amplify Snack Brands, Jose Cuervo and Vaxxinity, and other public and private equity offerings for companies such as AXIS, Orbotech, Orcosa, People’s United and Replimune
- Debt financings for companies such as AmerisourceBergen, AXIS, Hess Infrastructure Partners, INEOS, Marathon Oil, TransDigm, Valvoline and Xerox
- Investor representations such as a large investor in connection with the $5.1 billion IPO of Lineage; Shaolin Capital Management in its $50 million PIPE investment in connection with the business combination of Bitcoin Depot and GSR II Meteora Acquisition Corp.; Brevan Howard Digital in connection with a variety of investments in digital asset and blockchain companies; and DRI Capital in its equity investment in KalVista Pharmaceuticals
- Representing Route Mobile and its founding shareholders in the sale of a majority stake in Route Mobile to Proximus Group, WiseTech Global in its acquisition of Envase Technologies, Synthomer in its acquisition of OMNOVA, Deutsche Börse in its acquisition of Axioma and Orbotech in its sale to KLA‑Tencor
- Representing various private technology and life sciences companies in general corporate and financing matters, including those involving traditional and synthetic royalty interests
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Education
-
J.D., 2016, Fordham University School of Lawmagna cum laude
-
B.A., 2011, University of Nebraska-Lincolnsumma cum laude
Admitted In
- New York
Deals & Cases
November 04, 2024
DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
July 17, 2023
Route Mobile’s Sale of a Majority Stake to Proximus Group
On July 17, 2023, Proximus Group announced that it has signed a definitive agreement to acquire, through Proximus Opal, an approximately 58% interest in Route Mobile, a global company specialized in CPaaS services, from the founding shareholders of Route Mobile. As part of the agreement, some of the founding shareholders will reinvest in a minority stake in Proximus Opal, a subsidiary of the Proximus Group and the holding company of Telesign, Proximus’s U.S.‑based affiliate. Cravath, alongside Slaughter and May, AZB & Partners and NautaDutilh, is representing Route Mobile and its founding shareholders in connection with the transaction.
Publications
February 06, 2025
Cravath Venture Capital & Growth Equity Insights: 2024 Recap and 2025 Outlook
On February 5, 2025, Cravath published the latest edition of its Cravath Venture Capital & Growth Equity Insights newsletter (formerly the Cravath Emerging Company and Venture Capital Insights newsletter), entitled “2024 Recap and 2025 Outlook.” The newsletter provides an overview of global venture capital and related activity during the second half of 2024 and examines emerging fundraising opportunities, key exit trends and increasing secondaries markets activity; offers insights on artificial intelligence investment and cryptocurrency valuation; and provides updates on regulatory developments.
Publications
June 06, 2024
Nick Dorsey and Virginia Anderson Co‑Author U.S. Chapter of 2024 Chambers Venture Capital Guide
Cravath partner Nicholas A. Dorsey and of counsel Virginia M. Anderson co‑authored the U.S. Law & Practice chapter of the Chambers Venture Capital Guide, which was published in May 2024. The guide, which is part of the publisher’s Global Practice Guides series, provides the latest legal information on trends in the venture capital market; fund structures, economics and regulation; investments in VC companies; government subsidies and tax; and employee incentivization in the 20 jurisdictions covered. The U.S. Law & Practice chapter examined the increase in U.S. venture capital funding in artificial intelligence in 2023; the emergence of “down round” raises, bridge financing solutions and alternative financing solutions for companies that have faced financing challenges; typical venture capital fund structure in the U.S.; and more.
Firm News
November 20, 2023
Cravath Announces New Of Counsels and Senior Attorneys
On November 17, 2023, Virginia M. Anderson, D. Ana Choi, Christopher P. Davis, Janice T.P. Martindale, Flora Ng, Nicole M. Peles, Scott B. Reents and Kathryn‑Ann Stamm were named of counsels of the Firm and Jean Kearns and DongHwa Kim were named senior attorneys of the Firm, effective January 1, 2024.
Virginia M. Anderson represents clients in connection with public and private securities offerings and other financing transactions, general corporate matters and mergers and acquisitions. She is a member of the Venture Capital & Growth Equity Practice, where she frequently represents venture capital‑backed companies and investors, as well as other growth‑stage companies and investors, in financing transactions and other matters throughout their lifecycles.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
- IPOs for companies such as Amplify Snack Brands, Jose Cuervo and Vaxxinity, and other public and private equity offerings for companies such as AXIS, Orbotech, Orcosa, People’s United and Replimune
- Debt financings for companies such as AmerisourceBergen, AXIS, Hess Infrastructure Partners, INEOS, Marathon Oil, TransDigm, Valvoline and Xerox
- Investor representations such as a large investor in connection with the $5.1 billion IPO of Lineage; Shaolin Capital Management in its $50 million PIPE investment in connection with the business combination of Bitcoin Depot and GSR II Meteora Acquisition Corp.; Brevan Howard Digital in connection with a variety of investments in digital asset and blockchain companies; and DRI Capital in its equity investment in KalVista Pharmaceuticals
- Representing Route Mobile and its founding shareholders in the sale of a majority stake in Route Mobile to Proximus Group, WiseTech Global in its acquisition of Envase Technologies, Synthomer in its acquisition of OMNOVA, Deutsche Börse in its acquisition of Axioma and Orbotech in its sale to KLA‑Tencor
- Representing various private technology and life sciences companies in general corporate and financing matters, including those involving traditional and synthetic royalty interests
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
- IPOs for companies such as Amplify Snack Brands, Jose Cuervo and Vaxxinity, and other public and private equity offerings for companies such as AXIS, Orbotech, Orcosa, People’s United and Replimune
- Debt financings for companies such as AmerisourceBergen, AXIS, Hess Infrastructure Partners, INEOS, Marathon Oil, TransDigm, Valvoline and Xerox
- Investor representations such as a large investor in connection with the $5.1 billion IPO of Lineage; Shaolin Capital Management in its $50 million PIPE investment in connection with the business combination of Bitcoin Depot and GSR II Meteora Acquisition Corp.; Brevan Howard Digital in connection with a variety of investments in digital asset and blockchain companies; and DRI Capital in its equity investment in KalVista Pharmaceuticals
- Representing Route Mobile and its founding shareholders in the sale of a majority stake in Route Mobile to Proximus Group, WiseTech Global in its acquisition of Envase Technologies, Synthomer in its acquisition of OMNOVA, Deutsche Börse in its acquisition of Axioma and Orbotech in its sale to KLA‑Tencor
- Representing various private technology and life sciences companies in general corporate and financing matters, including those involving traditional and synthetic royalty interests
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Education
-
J.D., 2016, Fordham University School of Lawmagna cum laude
-
B.A., 2011, University of Nebraska-Lincolnsumma cum laude
Admitted In
- New York
Deals & Cases
November 04, 2024
DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
July 17, 2023
Route Mobile’s Sale of a Majority Stake to Proximus Group
On July 17, 2023, Proximus Group announced that it has signed a definitive agreement to acquire, through Proximus Opal, an approximately 58% interest in Route Mobile, a global company specialized in CPaaS services, from the founding shareholders of Route Mobile. As part of the agreement, some of the founding shareholders will reinvest in a minority stake in Proximus Opal, a subsidiary of the Proximus Group and the holding company of Telesign, Proximus’s U.S.‑based affiliate. Cravath, alongside Slaughter and May, AZB & Partners and NautaDutilh, is representing Route Mobile and its founding shareholders in connection with the transaction.
Publications
February 06, 2025
Cravath Venture Capital & Growth Equity Insights: 2024 Recap and 2025 Outlook
On February 5, 2025, Cravath published the latest edition of its Cravath Venture Capital & Growth Equity Insights newsletter (formerly the Cravath Emerging Company and Venture Capital Insights newsletter), entitled “2024 Recap and 2025 Outlook.” The newsletter provides an overview of global venture capital and related activity during the second half of 2024 and examines emerging fundraising opportunities, key exit trends and increasing secondaries markets activity; offers insights on artificial intelligence investment and cryptocurrency valuation; and provides updates on regulatory developments.
Publications
June 06, 2024
Nick Dorsey and Virginia Anderson Co‑Author U.S. Chapter of 2024 Chambers Venture Capital Guide
Cravath partner Nicholas A. Dorsey and of counsel Virginia M. Anderson co‑authored the U.S. Law & Practice chapter of the Chambers Venture Capital Guide, which was published in May 2024. The guide, which is part of the publisher’s Global Practice Guides series, provides the latest legal information on trends in the venture capital market; fund structures, economics and regulation; investments in VC companies; government subsidies and tax; and employee incentivization in the 20 jurisdictions covered. The U.S. Law & Practice chapter examined the increase in U.S. venture capital funding in artificial intelligence in 2023; the emergence of “down round” raises, bridge financing solutions and alternative financing solutions for companies that have faced financing challenges; typical venture capital fund structure in the U.S.; and more.
Firm News
November 20, 2023
Cravath Announces New Of Counsels and Senior Attorneys
On November 17, 2023, Virginia M. Anderson, D. Ana Choi, Christopher P. Davis, Janice T.P. Martindale, Flora Ng, Nicole M. Peles, Scott B. Reents and Kathryn‑Ann Stamm were named of counsels of the Firm and Jean Kearns and DongHwa Kim were named senior attorneys of the Firm, effective January 1, 2024.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.